$APLT

Applied Therapeutics Inc

  • NASDAQ
  • Biotechnology
  • Health Technology
  • Pharmaceuticals: Major

PRICE

$1.6 ▲3.896%

Extented Hours

VOLUME

116,649

DAY RANGE

1.4 - 1.51

52 WEEK

1.33 - 25.59

Join Discuss about APLT with like-minded investors

profile
@dros #droscrew
recently

Upgrades 8/27: $BAP $FTCH $OLLI $PLAY $PTON  . Downgrades 8/27: $AAP $APLT $AZO $BIG $CNX $DLTR $EYE $FIVE $HPQ $MRVL $ORLY $PTR $ULTA

147 Replies 14 👍 10 🔥

Key Metrics

Market Cap

37.26 M

Beta

1.64

Avg. Volume

136.09 K

Shares Outstanding

26.24 M

Yield

0%

Public Float

0

Next Earnings Date

2022-08-11

Next Dividend Date

Company Information

Applied Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need. The Company's lead drug candidate, AT-007, is a novel central nervous system penetrant aldose reductase inhibitor (ARI) for the treatment of Galactosemia, a rare pediatric metabolic disease. The Company initiated a pivotal Phase 1/2 clinical trial in June 2019, read out positive top-line biomarker data in adult Galactosemia patients in January 2020 and announced full data from the trial in April 2020. A pediatric Galactosemia study commenced in June 2020. The Company is also developing AT-001, a novel potent ARI that is being developed for the treatment of Diabetic Cardiomyopathy, or DbCM, a fatal fibrosis of the heart. The Company initiated a Phase 3 registrational study in DbCM in September 2019. The preclinical pipeline also includes AT-003, an ARI designed to cross through the back of the eye when dosed orally, for the treatment of diabetic retinopathy, as well as novel dual PI3k inhibitors in preclinical development for orphan oncology indications.

Website:

HQ: 545 5Th Avenue, Suite 1400 New York, 10017 New York

Related News